Jump to
About clinical trials
About clinical trials
Contact information: breast
Contact information: GI
Contact information: thoracic
Contact information: leukemia
Contact information: lymphoma
Contact information: multiple myeloma
Contact information: hematology
Contact information: head and neck
Contact information: melanoma
Contact information: prevention
Contact information: GU
Contact information: GYN

About clinical trials

For some patients, clinical trials offer a source of hope that a new treatment will provide the medical intervention they need to win their battle against cancer. These treatment trials also provide the critical research necessary to continue the search for a cure.

Cancer patients treated in well-organized clinical trials, in general, do as well or better than patients receiving "standard" treatments, particularly in difficult cancers where traditional treatments have not had a high success rate.

Experiencing tremendous growth since its establishment, the Penn State Hershey Cancer Institute at Mount Nittany Medical Center continues to participate in clinical research.

Please direct any questions to a Penn State Hershey Cancer Institute trials office staff member.



Contact information: breast

NRG-BR003:

A Randomized Phase III Trial of Adjuvent Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-positive or High-risk Node-negative Triple-negative Invasive Breast Cancer. NRG-BR003 Clinical Abstract (PDF)

A011401:

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer. A011401 Clinical Abstract (PDF)



Contact information: GI

FORCE: 

Focus on Reducing Dose-limiting Toxicities in Colon Cancer with Resistance Exercise. FORCE Clinical Abstract (PDF)



Contact information: thoracic

A151216:

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). A151216 Clinical Abstract (PDF)

A081105:

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC). A081105 Clinical Abstract (PDF)

E4512:

A Phase III Double-Blind Trial for Surgically Resected Early State Non-small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (An Alchemist Treatment Trial). E4512 Clinical Abstract (PDF)

EA5142:

Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers. E5142 Clinical Abstract (PDF)

JoLT-Ca STABLE-MATES Trial (STU 022015-0690):

A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with State I Non-small Cell Lung Cancer (NSCLC). JoLT-Ca STABLE-MATES Clinical Abstract (PDF)



Contact information: leukemia

There are no trials at this time.

Contact information: lymphoma

There are no trials at this time.

Contact information: multiple myeloma

There are no trials at this time.

Contact information: hematology

Dr. Zheng — Collection of Blood for Investigation and Characterization of Circulating Tumor Cells (CTCs) in Cancer Patients with Microdevices Clinical Abstract (PDF)

Contact information: head and neck

iMACES Chemo Brain:

Imaging and Mobile Assessments of Cognition, Environment and Sleep Study. iMACES Chemo Brain Clinical Abstract (PDF)



Contact information: melanoma

There are no trials at this time.

Contact information: prevention

There are no trials at this time.

Contact information: GU

There are no trials at this time.

Contact information: GYN

There are no trials at this time.